Nycole was compensated by Neurocrine Biosciences, Inc. to share her story. As a result of being on those medications, Nycole developed tardive dyskinesia (TD), a condition that affects approximately ...
Tardive dyskinesia (TD) and drug-induced parkinsonism (DIP) are most commonly associated with dopamine receptor blocking agents, such as antipsychotic medications. While newer, atypical antipsychotics ...
—According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...
-- New Three-Year Gene Therapy Data for Parkinson's Disease Part of 30 Abstracts to be Presented at 2020 Psych Congress and the MDS Virtual Congress 2020 -- - INGREZZA® (valbenazine) Data Analyses ...
The findings of this study align with prior research that suggests lower effective doses of clozapine are required for patients of Indian descent compared to Western populations. Switching patients of ...
SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of improvement over ...
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA ® (valbenazine) capsules, published in the Journal of Affective ...
TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label ...
TRENTON, N.J. (AP) — U.S. regulators have approved the first drug for treating a neurological syndrome that causes uncontrollable body movements that can also interfere with speech, swallowing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback